Topotecan plus carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a meta-analysis of randomized controlled trials
Authors: Zhang, Hui; Jia, Lin; Xu, Yintao; Zhou, Xun Clare; Kong, Beihua; Li, Dadong
Source: Journal of Chemotherapy, Volume 24, Number 2, April 2012 , pp. 67-73(7)
Publisher: Maney Publishing
Objective: To evaluate whether the addition of topotecan can improve the efficacy of carboplatin and paclitaxel in first-line treatment of advanced epithelial ovarian cancer.
Methods: Meta-analysis was performed using a random effects model.
Results: Four randomized controlled trials with a total of 3632 patients were identified and included in the meta-analysis. No significant differences were observed in terms of progression-free survival (P = 0·400), overall survival (P = 0·502) and overall response rate (P = 0·953) between patients treated with topotecan plus carboplatin and paclitaxel versus carboplatin and paclitaxel. However, there were significantly higher rates of grade 3‐4 leucopenia (P = 0·024), neutropenia (P<0·001), anaemia (P<0·001), and thrombopenia (P<0·001) in the topotecan plus carboplatin and paclitaxel group. No significant differences were observed in grade 3‐4 nausea (P = 0·352) and vomiting (P = 0·092) between these two groups.
Conclusion: Topotecan plus carboplatin and paclitaxel did not improve survival outcomes and caused more haematological toxicity for advanced ovarian cancer.
Document Type: Research Article
Affiliations: Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, China
Publication date: 2012-04-01